Develops oral small-molecule medicines that remove disease-causing proteins, primarily for people with immune-inflammatory diseases.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of…View ↗
Our current discovery and development efforts are primarily directed at high-value targets in immunology. We believe there are more than…View ↗
Our publicly disclosed immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways…View ↗
Collaborators pay Kymera for licenses to its drug technology and for research and development work. License fees may be paid upfront or when an option is exercised; research payments arrive under contract billing schedules, with some earned as the work progresses.
10-K for FY2025, filed Feb 26, 2026For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the…View ↗
Exclusive Licenses—If the license granted in the arrangement is determined to be distinct from the other promises or performance…View ↗
Research and Development Services—The promises under the Company’s collaboration and license agreements generally include research and…View ↗
Customer Options—The Company’s arrangements may provide a collaborator with the right to certain optional purchases, such as the right to…View ↗
$39.2M
10-K for FY2025, filed Feb 26, 2026
$39.2M ↗
Pharmaceutical collaborators buy licenses to Kymera’s drug technology and contract research and development work.
10-K for FY2025, filed Feb 26, 2026Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods…View ↗
Exclusive Licenses—If the license granted in the arrangement is determined to be distinct from the other promises or performance…View ↗
Research and Development Services—The promises under the Company’s collaboration and license agreements generally include research and…View ↗
No. It lost $311.4M in FY2025.
10-Q for Q3 FY2026, filed Oct 29, 2026
−$132MView ↗
8-K, filed Jun 25, 2026
On June 25, 2026, the Company announced that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its…View ↗
Shrinking. Revenue fell 46% in 4 years, from $72.8M in FY2021 to $39.2M in FY2025, about 14% a year.
From oncology to immunology
The older report described clinical programs across immune-inflammatory diseases and cancer. The latest report centers its disclosed clinical pipeline on immune-inflammatory diseases.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026
Competes with Arvinas, C4 Therapeutics, Nurix Therapeutics, Foghorn Therapeutics, Gilead Sciences, Johnson & Johnson, Pfizer, and Sanofi
10-K for FY2025, filed Feb 26, 2026Companies developing small molecule protein degraders therapies for patients, include, but are not limited to, Arvinas, Inc., C4…View ↗
Loading...